Leishmaniases belong to the inglorious group of neglected tropical diseases, presenting different degrees of manifestations severity. It is caused by the transmission of more than 20 species of parasites of the Leishmania genus. Nevertheless, the disease remains on the priority list for developing new treatments, since it affects millions in a vast geographical area, especially low-income people. Molecular biology studies are pioneers in parasitic research with the aim of discovering potential targets for drug development. Among them are the telomeres, DNA–protein structures that play an important role in the long term in cell cycle/survival. Telomeres are the physical ends of eukaryotic chromosomes. Due to their multiple interactions with different proteins that confer a likewise complex dynamic, they have emerged as objects of interest in many medical studies, including studies on leishmaniases. This review aims to gather information and elucidate what we know about the phenomena behind Leishmania spp. telomere maintenance and how it impacts the parasite’s cell cycle.
Trypanosoma cruzi is the etiological agent of Chagas disease (CD). During its life cycle, T. cruzi undergoes several key differentiation processes that are essential for its survival. The precise mechanisms that regulate these processes remain elusive, and any interference in this cycle would represent a breakthrough in the development of effective therapy against CD. Here we show that key differentiation processes of T. cruzi (metacyclogenesis, amastigogenesis and trypomastigogenesis) are profoundly impaired in response to low inositol hexakisphosphate kinase (IP6K) levels. Epimastigote forms of IP6K-deficient T. cruzi exhibit morphological alterations and reduced metacyclogenesis. IP6K-deficient metacyclic forms show reduced infective potential in human cardiomyocytes. IP6K-deficient amastigote forms present impaired ability to transform into trypomastigotes, with most of the population egressing from human cardiomyocytes without completing trypomastigogenesis. Although IP6K catalyzes the formation of inositol pyrophosphates (IP7), the levels of this metabolite do not undergo significant reduction in response to low IP6K levels, suggesting that this kinase sustains the T. cruzi life cycle through non-canonical functions. Since total depletion of IP6K is lethal and the primary structure of IP6K shares only ~25% similarity with its human homolog, this kinase emerges as a promising target for drug development against CD.
Trypanosoma cruzi is the etiological agent of Chagas disease. During its life cycle, T. cruzi undergoes several key differentiation processes that are essential for its survival. The precise mechanisms that regulate these processes remain elusive, and any interference in this cycle would represent a breakthrough in the development of effective therapy against Chagas disease. Here, after depleting a single IP6K allele of T. cruzi , we observed that key differentiation processes (metacyclogenesis, amastigogenesis and trypomastigogenesis) were profoundly impaired. Epimastigote forms of IP6K-deficient T. cruzi exhibited morphological alterations and reduced metacyclogenesis. IP6K-deficient metacyclic forms had reduced infective potential in human cardiomyocytes. IP6K-deficient amastigote forms showed impaired ability to transform into trypomastigotes, with most of the population egressing from human cardiomyocytes without completing trypomastigogenesis. Together, our results suggest that IP6K is critical to sustain the T. cruzi life cycle. Since disruption of both IP6K alleles was lethal and the primary structure of IP6K shares only ∼25% similarity with its human homolog, this kinase emerges as a promising target for drug development against Chagas disease. Graphical